BDSX biodesix.com Earnings per share growth in current year

Official company branding of Biodesix, Inc. (BDSX)

The business foundation of Biodesix, Inc. (BDSX) consists of autonomous high-tech laboratories in Kansas and Colorado, which is visualized through measurable YoY EPS growth. The value of 36.90 represents the current metric level, confirming the impact of expanded partnerships and test volumes. However, slow insurance reimbursement and high marketing costs create risks of prolonged losses, driving the price action on this chart.

Earnings per share growth in current year: Biodesix Corp (BDSX) for 07/04/2022 - 11/15/2026

Analytical breakdowns and data insights for company Biodesix Inc (BDSX)

- market value and analyst target forecast:
Stock Price Biodesix Corporation|BDSX - Price Target Chart
- market capitalization data:
Market Value Biodesix Inc|BDSX - Real Price to Acquire Entire Company
- book capitalization indicators:
Net Asset Value per Share Biodesix|BDSX - Company Book Value|Market Capitalization to Book Value biodesix.com|BDSX - Company Total Assets
- debt and solvency information:
Total Debt to Capital Coefficient Biodesix, Inc.|BDSX - Long-Term Debt to Equity|Short-Term Debt to Capital Coefficient Biodesix|BDSX - Company Aggregate Debts|Debt to Book Capitalization Ratio Biodesix|BDSX - Company Long-Term Debts|Short-Term Debt Volume Biodesix|Immediate Liquidity biodesix.com
- company profitability and valuation multiples indicators:
BDSX - Net Profit|Net Profit Forecast Biodesix, Inc.|BDSX - P/E Multiple|Projected Price to Earnings Ratio biodesix.com|BDSX - Price/Earnings to Growth Ratio|Total Company Value to Operating Income Before Depreciation Ratio Biodesix|BDSX - Operating profit EBITDA|Net earnings per share for the last four quarters Biodesix|BDSX - Net earnings per share for the last 12 months|Year-over-year earnings per share growth for the last 12 months biodesix.com|BDSX - Net earnings per share growth this year|Expected earnings per share trend next year Biodesix, Inc.
- revenue and sales proceeds data:
BDSX - Revenue and Sales Volume|Company Future Sales Biodesix Corporation|BDSX - Price-to-Revenue Ratio|Market Cap to Projected Revenue Biodesix|BDSX - Sales Growth YoY (TTM)
Fundamental valuation:Biodesix Corp, BDSX
Mass-produced product of Biodesix

Fundamental EPS analysis minimizes risks by assessing the actual efficiency of capital management. For Biodesix, Inc. (BDSX), a leader in AI-powered rapid lung cancer diagnostics, this is a critical marker of business scalability. Comparing annual EPS growth measures the percentage change in net income per share relative to the previous year. This indicator's trend reflects the company's ability to convert its technological advantage into financial results. Increasing values confirm the model's resilience to operating expenses.

Direct competitors

CAI (Caris Life Sciences, Inc.) - Earnings per share growth in current year|Earnings per share growth in current year guardanthealth.com|Earnings per share growth in current year VCYT|Net earnings per share growth this year CELC (Celcuity Therapeutics)|GRAL - Earnings per share growth rate in current year|Earnings per share growth in current year Myriad MYGN|Expected net earnings per share growth this year Castle Biosciences Corp (CSTL)|BNR - Earnings per share growth in current year|Expected net earnings per share growth this year VolitionRx VNRX|Precipio Inc. (PRPO) - Earnings per share growth in current year|CHEK - Expected net earnings per share growth this year|Earnings per share growth in current year mainzbiomed.com|Earnings per share growth this year OCX (OncoCyte Corp.)